Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC for Autologous Fat Graft Survival
NCT02788292Phase 4Withdrawn
- Sponsor
- Nova Scotia Health
- Start
- Aug 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, triple-blind trial of acetylcysteine in lipodystrophy, Breast deformity and Graft loss (GF) (2 arms), sponsored by Nova Scotia Health. Primary endpoint: Change in fat graft volume over time at 3 months. Planned start Aug 2016; status: withdrawn.
02
Drugs
acetylcysteine
03
Conditions
lipodystrophyBreast deformityGraft loss (GF)
Beyond the preview
Go deeper on NCT02788292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788292.